Genupro subsidiary has dapoxetine in Phase II trials for premature ejaculation, CEO Fred Eshelman reported during an April 21 conference call. The company has enrolled 138 of a planned 150 patients in the study. Proof of concept may be established in the third quarter, at which time Lilly has the option to re-license the drug in exchange for a milestone payment. Genupro was established last year to develop genitourinary compounds licensed from Lilly
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth